Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic profile with participation of adult volunteers
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy patients | Experimental | Drug: GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile); A total of 50 people will be randomized and receive the study drug (vaccine). Two intramuscular injections of the investigational medicinal product (IMP) will be performed. 1st injection - component I, 2nd injection - component II. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) | Biological | Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II. |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of adverse events (AE) | Occurrence of adverse events (AE) | Within 28 days after administration of the drug |
| Occurrence of serious adverse events (SAEs) | Occurrence of serious adverse events (SAEs) | Throughout Study completion, until December 2024 |
Not provided
Not provided
Inclusion Criteria:
The study will include volunteers who meet all the specified criteria:
Exclusion Criteria:
Volunteers cannot be included in the Study if there is at least one of the following criteria for non-inclusion:
Not provided
Not provided
Not provided
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41972135 | Derived | Shuliakova IV, Grousova DM, Iliukhina AA, Dzharullaeva AS, Lubenets NL, Ordzhonikidze MK, Izhaeva FM, Erokhova AS, Zorkov ID, Azizyan VV, Boeva ZD, Reshetnikov DA, Ermolova IA, Lega VA, Kovyrshina AV, Bukhtin KM, Romanova LP, Alekseeva EI, Borzakova SN, Rachina SA, Rusanova MG, Ozharovskaia TA, Popova O, Zrelkin DI, Zubkova OV, Tukhvatulin AI, Tukhvatulina NM, Shcheblyakov DV, Favorskaya IA, Esmagambetov IB, Karpov AP, Semikhin AS, Pochtovyi AA, Naroditskiy BS, Gushchin VA, Gintsburg AL, Logunov DY. Sputnik V update: safety and neutralizing antibodies in healthy adults and adolescents. Front Immunol. 2026 Mar 26;17:1736771. doi: 10.3389/fimmu.2026.1736771. eCollection 2026. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided